Rafael Holdings, Inc. (RFL)
Company Description
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel.
It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.
Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.
The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors.
In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation.
Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Country | United States |
Industry | Real Estate Services |
Sector | Real Estate |
Employees | 13 |
CEO | William Conkling |
Contact Details
Address: 520 Broad Street Newark, New Jersey 07120 United States | |
Phone | 212-658-1450 |
Website | rafaelholdings.com |
Stock Details
Ticker Symbol | RFL |
Exchange | NYSE |
Fiscal Year | August - July |
Reporting Currency | USD |
CIK Code | 0001713863 |
CUSIP Number | 75062E106 |
ISIN Number | US75062E1064 |
Employer ID | 82-2296593 |
SIC Code | 6500 |
Key Executives
Name | Position |
---|---|
Howard S. Jonas | Founder and Executive Chairman |
William Conkling | Chief Executive Officer and President |
David A. Polinsky Esq. | Chief Financial Officer |
Barbara A. Ryan | Investor Relations Officer |
Gus Kodersha | Chief Technical Operations Officer |
Dr. Rick Ewing | Head of Drug Discovery |
Dr. John Mayer Goldberg M.D. | Chief Medical Officer |
Joyce J. Mason Esq. | Corporate Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 14, 2024 | 10-Q | Quarterly Report |
Mar 14, 2024 | 8-K | Current Report |
Mar 13, 2024 | 8-K | Current Report |
Jan 16, 2024 | 8-K | Current Report |
Dec 14, 2023 | 10-Q | Quarterly Report |
Dec 14, 2023 | 8-K | Current Report |
Nov 20, 2023 | DEFR14A | Filing |
Nov 20, 2023 | DEF 14A | Other definitive proxy statements |
Oct 30, 2023 | 10-K | Annual Report |
Oct 30, 2023 | 8-K | Current Report |